



Ifw

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/526,120 Confirmation No.: 2575
Applicant: Chua *et al.*
Filed: July 14, 2005
TC/A.AU.: 1644
Examiner: Nora Maureen Rooney

Docket No.: 11747.105002 NUS002
Customer No.: 20786
Title: Recombinant Nucleic Acid Useful for Inducing Protective Immune Response Against Allergens

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the accompanying Form PTO/SB/08A, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited reference is enclosed, except for the U.S. Patents and published U.S. Patent Applications. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicant does not believe that any fees are due because this paper is being submitted before the mailing of a first Office Action on the merits, as under 37 C.F.R. § 1.97(b)(3). However, should the Commissioner determine that fees are due, he is hereby authorized to charge such fees and to credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

Madeline I. Johnston, Ph.D., Esq.
Reg. No. 36,174

Dated: November 13, 2006
King & Spalding LLP
1180 Peachtree Street, 34th Floor
Atlanta, GA 30309-3521
Office: (404) 572-4600/ Fax: (404) 572-5134

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 13, 2006.

Diane M. Guilfoyle

4297848_1.DOC

Substitute for form 1449A/PTO

NOV 16 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	10/526,120
Filing Date	July 14, 2005
First Named Inventor	Chua <i>et al.</i>
Group Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	11747.105002 NUS002

4297845 1.DOC

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	4,722,848	A	Paoletti <i>et al.</i>	02-02-1988	
	AB	4,882,278	A	Mekalanos	11-21-1989	
	AC	4,920,209	A	Davis <i>et al.</i>	04-24-1990	
	AD	5,015,580	A	Christou <i>et al.</i>	05-14-1991	
	AE	5,168,062	A	Stinski	12-01-1992	
	AF	5,283,185	A	Epand <i>et al.</i>	02-01-1994	
	AG	5,364,773	A	Paoletti <i>et al.</i>	11-15-1994	
	AH	5,405,758	A	Oka <i>et al.</i>	04-11-1995	
	AI	5,433,948	A	Thomas <i>et al.</i>	07-18-1995	
	AJ	5,527,928	A	Nantz <i>et al.</i>	06-18-1996	
	AK	5,552,142	A	Thomas <i>et al.</i>	09-03-1996	
	AL	5,556,953	A	Zhang <i>et al.</i>	09-17-1996	
	AM	5,710,126	A	Griffith <i>et al.</i>	01-20-1998	
	AN	5,770,202	A	Thomas <i>et al.</i>	06-23-1998	
	AO	5,773,002	A	Thomas <i>et al.</i>	06-30-1998	
	AP	5,798,099	A	Yuuki <i>et al.</i>	08-25-1998	
	AQ	5,849,522	A	Fleckenstein <i>et al.</i>	12-15-1998	
	AR	5,869,288	A	Chapman <i>et al.</i>	02-09-1999	
	AS	5,876,722	A	Yuuki <i>et al.</i>	03-02-1999	
	AT	5,948,891	A	Staunton <i>et al.</i>	09-07-1999	
	AU	5,958,891	A	Hsu <i>et al.</i>	09-28-1999	
	AV	5,973,132	A	Thomas <i>et al.</i>	10-26-1999	
	AW	6,060,057	A	Thomas <i>et al.</i>	05-09-2000	
	AX	6,077,517	A	Thomas <i>et al.</i>	06-20-2000	
	AY	6,086,897	A	Thomas <i>et al.</i>	07-11-2000	
	AZ	6,147,201	A	Thomas <i>et al.</i>	11-14-2000	
	AAA	6,214,358	B1	Singh <i>et al.</i>	04-10-2001	
	AAB	6,268,491	B1	Garman <i>et al.</i>	07-31-2001	
	AAC	6,441,157	B1	Singh <i>et al.</i>	08-27-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Office ³	Number	Kind (if known)				
	AAD	WO	88/06626	A1	Whitehead Inst. Biomed. Res.	09-07-1988		

Examiner
SignatureDate Con-
sidered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number	10/526,120
Filing Date	July 14, 2005
First Named Inventor	Chua <i>et al.</i>
Group Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	11747.105002 NUS002

4297845 1.DOC

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Office ³	Number	Kind (if known)				
	BA	WO	90/00594	A2	Whitehead Inst., <i>et al.</i>	01-25-1990		
	BB	WO	90/11092	A1	Vical, Inc.; Wisc. Alum. R.F..	10-04-1990		
	BC	WO	91/00359	A1	Agracetus, Inc.	01-10-1991		
	BD	WO	91/13157	A1	Commonwealth Sci. Ind. Res.	09-05-1991		
	BE	WO	91/15501	A1	Yale Univ.	10-17-1991		
	BF	WO	92/01796	A1	SmithKlineBeecham Biol.	02-06-1992		
	BG	WO	92/11354	A1	Gen. Hosp. Corp.; Harvard	07-09-1992		
	BH	WO	92/11361	A1	Gen. Hosp. Corp.; Harvard	07-09-1992		
	BI	WO	92/21376	A1	Med Immune Inc.	12-10-1992		
	BJ	WO	93/17706	A1	Agracetus, Inc.	09-16-1993		
	BK	WO	93/18759	A1	Baylor Coll. Med.	09-30-1993		
	BL	WO	93/19768	A1	Univ. California	10-14-1993		
	BM	WO	94/01533	A1	Harvard Coll.; Virus Res. Inst.	01-20-1994		
	BN	WO	94/19482	A1	Gen. Hosp. Corp; Harvard	09-01-1994		
	BO	WO	94/25608	A1	Baylor Coll. Med.	11-10-1994		
	BP	WO	95/02397	A1	Univ. California	01-26-1995		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BQ	ARRUDA, L.K., "Sensitization to <i>Blomia tropicalis</i> in patients with asthma and identification of allergen Blo t 5," <i>Am. J. Respir. Crit. Care Med.</i> , 155(1):343-350 (January 1997).
	BR	BLAGOVESHCHENSKAYA, A.D., <i>et al.</i> , "A balance of opposing signals within the cytoplasmic tail controls the lysosomal targeting of P-selectin," <i>J. Biol. Chem.</i> , 273(43):27896-27903 (October 23, 1998).
	BS	BLAGOVESHCHENSKAYA, A.D., <i>et al.</i> , "Lysosomal targeting of P-selectin is mediated by a novel sequence within its cytoplasmic tail," <i>J. Biol. Chem.</i> , 273(5):2729-2737 (January 30, 1998).
	BT	BONIFAZ, L., <i>et al.</i> , "Efficient targeting of protein antigen to the dendritic cell receptor DEC- 205.in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance," <i>J. Exp. Med.</i> , 196(12):1627-1638 (December 16, 2002).
	BU	BOSHART, M., <i>et al.</i> , "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus," <i>Cell</i> , 41(2):521-530 (June 1985).
	BV	CALVO, P.A., <i>et al.</i> , "a cytoplasmic sequence in human tyrosinase defines a second class of di-leucine based sorting signals for late endosomal and lysosomal delivery," <i>J. Biol. Chem.</i> , 274(18):12780-12789 (April 30, 1999).

Examiner
SignatureDate Con-
sidered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/526,120
			Filing Date	July 14, 2005
			First Named Inventor	Chua <i>et al.</i>
			Group Art Unit	1644
			Examiner Name	Nora Maureen Rooney
			Attorney Docket Number	11747.105002 NUS002
Sheet	3	of	4	

4297845 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CA	CHEW, J.L., <i>et al.</i> , "Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice," <i>Vaccine</i> , 21(21-22):2720-2729 (June 20, 2003).
	CB	CHUA, K.Y., <i>et al.</i> , "Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases," <i>J. Exp. Med.</i> , 167(1):175-182 (January 1, 1988).
	CC	FLYNN, J.L., "Recombinant BCG as an antigen delivery system," <i>Cell. Mol. Biol. (Noisy-le-grand)</i> , 40 (Suppl. I):31-36 (1994).
	CD	FUKUMOTO, H., <i>et al.</i> , "Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin responsive tissues," <i>J. Biol. Chem.</i> , 264(14):7776-7779 (May 15, 1989).
	CE	GHOSH, P.K., <i>et al.</i> , "Identification of a promoter component involved in positioning the 5' termini of simian virus 40 early mRNAs," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 78(1):100-104 (January 1981).
	CF	GOKAY, K.E., "Cytoplasmic signals mediate apical early endosomal targeting of endotubulin in MDCK Cells," <i>Traffic</i> , 2(7):487-500 (July 2, 2001).
	CG	GOKAY, K.E., "Targeting of an apical endosomal protein to endosomes in Madin-Darby canine kidney cells requires two sorting motifs," <i>Traffic</i> , 1(4):354-365 (April 2000).
	CH	GORMAN, C.M., <i>et al.</i> , "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 79(22):6777-6781 (November 1982).
	CI	HIGH, N., <i>et al.</i> , "IpaB of Shigella flexneri causes entry into epithelial cells and escape from the phagocytic vacuole," <i>EMBO J.</i> , 11(5):1991-1999 (May 1992).
	CJ	JOHNSTON, G.I., <i>et al.</i> , "Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes," <i>J. Biol. Chem.</i> , 265(34):21381-21385 (December 5, 1990).
	CK	KATO, M., <i>et al.</i> , "cDNA cloning of human DEC-205, a putative antigen-uptake receptor on dendritic cells," <i>Immunogenetics</i> , 47(6):442-450 (May 1998).
	CL	KIENY, M.P., <i>et al.</i> , "Expression of rabies virus glycoprotein from a recombinant vaccinia virus," <i>Nature</i> , 312(5990):163-166 (November 8-14, 1984).
	CM	KWON, S.S., <i>et al.</i> , "The effect of vaccination with DNA encoding murine T-cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis," <i>Allergy</i> , 56(8):741-748 (August 2001).
	CN	McCUTCHAN, T.F., <i>et al.</i> , "DNA sequences similar to those around the simian virus 40 origin of replication are present in the monkey genome," <i>Proc. Natl. Acad. Sci. USA</i> , 78(1):95-99 (January 1981).
	CO	MEDAGLINI, D., <i>et al.</i> , "Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 92(15):6868-6872 (July 18, 1995).
	CP	MEKALANOS, J.J., <i>et al.</i> , "Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development," <i>Nature</i> , 306(5943):551-557 (December 8-14, 1983).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/526,120	
			Filing Date	July 14, 2005	
			First Named Inventor	Chua <i>et al.</i>	
			Group Art Unit	1644	
			Examiner Name	Nora Maureen Rooney	
Sheet	4	of	4	Attorney Docket Number	11747.105002 NUS002

4297845 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	DA	NAKAYAMA, K., <i>et al.</i> , "Construction of an ASD+ Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a <i>Salmonella</i> Vaccine Strain," <i>Nature Biotechnology (Bio/Technology)</i> , 6:693-697 (1988).
	DB	NIWA, H., <i>et al.</i> , "Efficient selection for high-expression transfectants with a novel eukaryotic vector," <i>Gene</i> , 108(2):193-199 (December 15, 1991).
	DC	NORCOTT, J.P., <i>et al.</i> , "Targeting of P-selectin to two regulated secretory organelles in PC12 cells, <i>J. Cell Biol.</i> 134(5):1229-1240 (September 1996).
	DD	RODRIGUEZ, F., <i>et al.</i> , "CD4+ T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting," <i>J. Virology</i> , 75(21):10421-10430.(November 2001).
	DE	SANDOVAL, I.V., <i>et al.</i> , "The residues Leu(Ile)475-Ile(Leu, Val, Ala)476, contained in the extended carboxyl cytoplasmic tail, are critical for targeting of the resident lysosomal membrane protein LIMP II to lysosomes," <i>J. Biochemistry</i> , 269(9): 6622-6631 (March 4, 1994).
	DF	SHEWAN, A.M., <i>et al.</i> , "The cytosolic C terminus of the glucose transporter GLUT4 contains an acidic cluster endosomal targeting motif distal to the dileucine signal," <i>Biochem. J.</i> , 350 Pt 1:99-107 (August 15, 2000).
	DG	SIZEMORE, D.R., <i>et al.</i> , "Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization," <i>Science</i> , 270(5234):299-302 (October 13, 1995).
	DH	STRAUSBERG, R.L., <i>et al.</i> , "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences," <i>Proc. Natl Acad. Sci. USA</i> , 99(26):16899-903 (December 24, 2002) (Epub December 11, 2002).
	DI	TANG, D.C., <i>et al.</i> , "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> 356(6365):152-154 (March 12, 1992).
	DJ	TARTAGLIA, J., <i>et al.</i> , "NYVAC: a highly attenuated strain of vaccinia virus," <i>Virology</i> , 188(1):217-232 (May 1992).
	DK	TAYLOR, J., <i>et al.</i> , "Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species," <i>Vaccine</i> , 13(6):539-549 (April 1995).
	DL	USHIYAMA, S., <i>et al.</i> , "Structural and functional characterization of monomeric soluble P-selectin and comparison with membrane P-selectin," <i>J. Biol. Chem.</i> , 268(20):15229-15237 (July 15, 1993).
	DM	VEGA, M.A., <i>et al.</i> , "Cloning, sequencing, and expression of a cDNA encoding rat LIMP 11, a novel 74-kDa lysosomal membrane protein related to the surface adhesion protein CD36," <i>J. Biol. Chem.</i> , 266(25):16818-16824 (September 5, 1991).
	DN	VEGA, M.A., <i>et al.</i> , "Targeting of lysosomal integral membrane protein LIMP II. The tyrosine-lacking carboxyl cytoplasmic tail of LIMP II is sufficient for direct targeting to lysosomes," <i>J. Biol. Chem.</i> , 266(25):16269-16272 (September 5, 1991).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.